Literature DB >> 33738061

Novel Potent Selective Orally Active S1P5 Receptor Antagonists.

Bin Ma1, Kevin M Guckian1, Xiao-Gao Liu1, Chunhua Yang1, Bing Li1, Robert Scannevin1, Michaël Mingueneau1, Annabelle Drouillard2,3, Thierry Walzer2,3.   

Abstract

S1P5 is one of the five sphingosine-1-phosphate (S1P) receptors which play important roles in immune and CNS cell homeostasis, growth, and differentiation. Little is known about the effect of modulation of S1P5 due to the lack of S1P5 specific modulators with suitable druglike properties. Here we describe the discovery and optimization of a novel series of potent selective S1P5 antagonists and the identification of an orally active brain-penetrant tool compound 15.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33738061      PMCID: PMC7957944          DOI: 10.1021/acsmedchemlett.0c00631

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  18 in total

1.  Design and synthesis of selective and potent orally active S1P5 agonists.

Authors:  Henri Mattes; Kumlesh Kumar Dev; Rochdi Bouhelal; Carmen Barske; Fabrizio Gasparini; Danilo Guerini; Anis Khusro Mir; David Orain; Maribel Osinde; Anne Picard; Celine Dubois; Engin Tasdelen; Samuel Haessig
Journal:  ChemMedChem       Date:  2010-10-04       Impact factor: 3.466

2.  FTY720 modulates human oligodendrocyte progenitor process extension and survival.

Authors:  Veronique E Miron; Cha Gyun Jung; Hye Jung Kim; Timothy E Kennedy; Betty Soliven; Jack P Antel
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

Review 3.  Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.

Authors:  Sinead O'Sullivan; Kumlesh K Dev
Journal:  Neuropharmacology       Date:  2016-11-04       Impact factor: 5.250

4.  S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate.

Authors:  Annabelle Drouillard; Anne-Laure Mathieu; Antoine Marçais; Alexandre Belot; Sébastien Viel; Michaël Mingueneau; Kevin Guckian; Thierry Walzer
Journal:  J Allergy Clin Immunol       Date:  2017-12-14       Impact factor: 10.793

Review 5.  Lysophospholipid receptors in the nervous system.

Authors:  Rachelle E Toman; Sarah Spiegel
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

Review 6.  Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.

Authors:  Timothy Hla; Volker Brinkmann
Journal:  Neurology       Date:  2011-02-22       Impact factor: 9.910

Review 7.  Sphingosine-1-phosphate regulation of mammalian development.

Authors:  Mari Kono; Maria Laura Allende; Richard L Proia
Journal:  Biochim Biophys Acta       Date:  2008-07-14

8.  Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.

Authors:  F L Scott; B Clemons; J Brooks; E Brahmachary; R Powell; H Dedman; H G Desale; G A Timony; E Martinborough; H Rosen; E Roberts; M F Boehm; R J Peach
Journal:  Br J Pharmacol       Date:  2016-04-28       Impact factor: 8.739

9.  Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.

Authors:  Veronique E Miron; Jeffery A Hall; Timothy E Kennedy; Betty Soliven; Jack P Antel
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

10.  Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.

Authors:  Adrian D Hobson; Christopher M Harris; Elizabeth L van der Kam; Sean C Turner; Ayome Abibi; Ana L Aguirre; Peter Bousquet; Tegest Kebede; Donald B Konopacki; Gary Gintant; Youngjae Kim; Kelly Larson; John W Maull; Nigel S Moore; Dan Shi; Anurupa Shrestha; Xiubo Tang; Peng Zhang; Kathy K Sarris
Journal:  J Med Chem       Date:  2015-11-23       Impact factor: 7.446

View more
  1 in total

1.  Structural basis for receptor selectivity and inverse agonism in S1P5 receptors.

Authors:  Elizaveta Lyapina; Egor Marin; Anastasiia Gusach; Philipp Orekhov; Andrey Gerasimov; Aleksandra Luginina; Daniil Vakhrameev; Margarita Ergasheva; Margarita Kovaleva; Georgii Khusainov; Polina Khorn; Mikhail Shevtsov; Kirill Kovalev; Sergey Bukhdruker; Ivan Okhrimenko; Petr Popov; Hao Hu; Uwe Weierstall; Wei Liu; Yunje Cho; Ivan Gushchin; Andrey Rogachev; Gleb Bourenkov; Sehan Park; Gisu Park; Hyo Jung Hyun; Jaehyun Park; Valentin Gordeliy; Valentin Borshchevskiy; Alexey Mishin; Vadim Cherezov
Journal:  Nat Commun       Date:  2022-08-12       Impact factor: 17.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.